<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024045</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-BCL-20001</org_study_id>
    <secondary_id>2021-000060-30</secondary_id>
    <secondary_id>J3N-OX-JZRA</secondary_id>
    <nct_id>NCT05024045</nct_id>
  </id_info>
  <brief_title>Study of Oral LOXO-338 in Patients With Advanced Blood Cancers</brief_title>
  <official_title>A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether the study drug, LOXO-338, is safe and&#xD;
      effective in patients with advanced blood cancer. Patients must have already received&#xD;
      standard therapy. The study may last up to approximately 3 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in 2 parts. Part 1 will evaluate LOXO-338 as monotherapy. If&#xD;
      safety and initial evidence of efficacy of LOXO-338 monotherapy are confirmed, part 2 will&#xD;
      evaluate the combination of LOXO-338 with the highly selective, noncovalent Bruton's tyrosine&#xD;
      kinase (BTK) inhibitor, pirtobrutinib (LOXO-305).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338</measure>
    <time_frame>Cycle 1 (28 Days)</time_frame>
    <description>Measured by the number of patients with dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - To determine the safety and tolerability of LOXO-338 when given in combination with pirtobrutinib</measure>
    <time_frame>Cycle 2 (28 Days)</time_frame>
    <description>Measured by the number of patients with dose-limiting toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 - To characterize the pharmacokinetics (PK) properties of LOXO-338: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>PK: AUC of LOXO-338</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 - To characterize the PK properties of LOXO-338: Maximum drug concentration (Cmax)</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>PK: Cmax of LOXO-338</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 - To assess preliminary antitumor activity of LOXO-338 based on overall response rate (ORR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 - To assess preliminary antitumor activity of LOXO-338 based on progression-free survival (PFS)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 - To assess preliminary antitumor activity of LOXO-338 based on time-to-progression (TTP)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>TTP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 - To assess preliminary antitumor activity of LOXO-338 based on duration of response (DOR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - To characterize the pharmacokinetics (PK) properties of LOXO-338 in combination with pirtobrutinib: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>PK: AUC of LOXO-338 alone and in combination with pirtobrutinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - To characterize the PK properties of LOXO-338 and in combination with pirtobrutinib: Maximum drug concentration (Cmax)</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>PK: Cmax of LOXO-338 alone and in combination with pirtobrutinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on overall response rate (ORR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on progression-free survival (PFS)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on time-to-progression (TTP)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>TTP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on duration of response (DOR)</measure>
    <time_frame>Estimated up to 2 years</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <condition>Lymphoma, B-cell Marginal Zone</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Multiple Myeloma</condition>
  <condition>B-cell Lymphoma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Lymphoma, Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>LOXO-338 (Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOXO-338 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOXO-338 + Pirtobrutinib (Combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOXO-338 administered orally in combination with pirtobrutinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-338</intervention_name>
    <description>Oral</description>
    <arm_group_label>LOXO-338 (Monotherapy)</arm_group_label>
    <arm_group_label>LOXO-338 + Pirtobrutinib (Combination)</arm_group_label>
    <other_name>LY3847429</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirtobrutinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>LOXO-338 + Pirtobrutinib (Combination)</arm_group_label>
    <other_name>LOXO-305</other_name>
    <other_name>LY3527727</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  B-cell malignancy.&#xD;
&#xD;
          -  Patients must have received prior therapy.&#xD;
&#xD;
          -  Patients must have an objective indication for therapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2.&#xD;
&#xD;
          -  Anticipated life expectancy of greater than or equal to (≥) 12 weeks.&#xD;
&#xD;
          -  Adequate bone marrow function.&#xD;
&#xD;
          -  Adequate hepatic function.&#xD;
&#xD;
          -  Creatinine clearance of ≥ 60 milliliters (mL)/minute.&#xD;
&#xD;
          -  Ability to swallow tablets.&#xD;
&#xD;
          -  Ability to comply with outpatient treatment, laboratory monitoring, and required&#xD;
             clinic visits for the duration of study participation.&#xD;
&#xD;
          -  Prior treatment-related adverse events (AEs) must have recovered to grade less than or&#xD;
             equal to (≤) 1 or pretreatment baseline, with the exception of alopecia.&#xD;
&#xD;
          -  Men with partners of childbearing potential or women of childbearing potential (WOCBP)&#xD;
             must agree to use highly effective birth control.&#xD;
&#xD;
          -  WOCBP must not be pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior to identification of the RP2D (Dose Expansion) of LOXO-338, a history of known,&#xD;
             active or suspected:&#xD;
&#xD;
               -  Richter's transformation to diffuse large B-cell lymphoma (DLBCL),&#xD;
                  prolymphocyticleukemia, or Hodgkin lymphoma&#xD;
&#xD;
               -  Transformed low grade lymphoma&#xD;
&#xD;
               -  Burkitt or Burkitt-like lymphoma&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Lymphoblastic lymphoma or leukemia&#xD;
&#xD;
               -  Posttransplant lymphoproliferative disorder&#xD;
&#xD;
          -  Known or suspected history of central nervous system (CNS) involvement.&#xD;
&#xD;
          -  History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen&#xD;
             receptor-modified T cell (CAR-T) therapy within the past 60 days and with any of the&#xD;
             following:&#xD;
&#xD;
               -  Active graft versus host disease (GVHD)&#xD;
&#xD;
               -  Cytopenias from incomplete blood cell count recovery post-transplant or CAR-T&#xD;
                  therapy&#xD;
&#xD;
               -  Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms&#xD;
                  of neurotoxicity Grade &gt; 1 from CAR-T therapy&#xD;
&#xD;
               -  Ongoing immunosuppressive therapy&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positive, regardless of cluster of&#xD;
             differentiation 4 (CD4) count. Unknown or negative status eligible.&#xD;
&#xD;
          -  Inability to take necessary uric acid lowering agents (i.e., allopurinol, rasburicase,&#xD;
             orfebuxostat).&#xD;
&#xD;
          -  Concurrent anticancer therapy.&#xD;
&#xD;
          -  Concurrent treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers&#xD;
             that can include antifungals.&#xD;
&#xD;
          -  Use of ≥ 20 milligrams (mg) prednisone once a day (QD) or equivalent dose of steroid&#xD;
             per day, within 7 days of start of study treatment. Patients may not be on any dose of&#xD;
             prednisone intended for antineoplastic use.&#xD;
&#xD;
          -  Vaccination with a live vaccine within 28 days prior to start of study therapy, with&#xD;
             the exception of vaccinations for coronavirus disease 2019 (COVID-19), as applicable.&#xD;
             Live vaccination for COVID-19 should occur at least two weeks prior to cycle 1, day 1&#xD;
             (C1D1).&#xD;
&#xD;
          -  Major surgery within four weeks of planned start of study therapy Prolongation of the&#xD;
             QT interval corrected by Fridericia's Formula for heart rate (QTcF) greater than (&gt;)&#xD;
             470 milliseconds (msec).&#xD;
&#xD;
          -  Clinically significant cardiovascular disease.&#xD;
&#xD;
          -  Female patient who is pregnant or lactating.&#xD;
&#xD;
          -  Active second malignancy which may preclude assessment of DLT.&#xD;
&#xD;
          -  Clinically significant active malabsorption syndrome including surgical resection of&#xD;
             small intestine or other condition likely to affect gastrointestinal (GI) absorption&#xD;
             of the orally administered study drugs.&#xD;
&#xD;
          -  Active hepatitis B or C infection.&#xD;
&#xD;
          -  Evidence of other clinically significant uncontrolled condition(s) including, but not&#xD;
             limited to, uncontrolled systemic infection (viral, bacterial, or fungal) or other&#xD;
             clinically significant active disease process.&#xD;
&#xD;
          -  Active uncontrolled auto-immune cytopenia.&#xD;
&#xD;
          -  Additional exclusion criteria for patients enrolled to part 2: LOXO-338 and&#xD;
             pirtobrutinib combination&#xD;
&#xD;
               -  Prior progression or intolerance to pirtobrutinib.&#xD;
&#xD;
               -  Patients requiring therapeutic anticoagulation with warfarin.&#xD;
&#xD;
               -  Known hypersensitivity to any component or excipient of pirtobrutinib.&#xD;
&#xD;
               -  In patients with history of myocardial infarction or congestive heart failure,&#xD;
                  documented left ventricular ejection fraction (LVEF) by any method of ≤ 45&#xD;
                  percent (%) in the 12 months prior to planned start of study treatment.&#xD;
&#xD;
               -  History of uncontrolled or symptomatic arrhythmias including grade ≥ 3 arrhythmia&#xD;
                  on a prior BTK inhibitor.&#xD;
&#xD;
               -  History of major bleeding on a prior BTK inhibitor.&#xD;
&#xD;
               -  Current treatment with strong permeability glycoprotein (P-gp) inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Pauff, MD; PhD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-855-LOXO-305</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BTKi</keyword>
  <keyword>Hematologic disease</keyword>
  <keyword>Small lymphocytic lymphoma</keyword>
  <keyword>BCL-2 inhibitor</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

